Literature DB >> 34610889

Metabolic regulation of the cancer-immunity cycle.

Luis F Somarribas Patterson1, Santosha A Vardhana2.   

Abstract

The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth. Interruption of one or more steps of the CIC enables tumors to evade immunosurveillance. However, attempts to restore antitumor immunity by reactivating the CIC have had limited success thus far. Recently, numerous studies have implicated metabolic reprogramming of tumor and immune cells within the tumor microenvironment (TME) as key contributors to immune evasion. In this opinion, we propose that alterations in cellular metabolism during tumorigenesis promote both initiation and disruption of the CIC. We also provide a rationale for metabolically targeting the TME, which may assist in improving tumor responsiveness to chimeric antigen receptor (CAR)-transduced T cells or immune checkpoint blockade (ICB) therapies.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CAR-T cells; PD-1; glycolysis; immunotherapy; lactate; metabolism; tumor immunology

Mesh:

Year:  2021        PMID: 34610889      PMCID: PMC8556351          DOI: 10.1016/j.it.2021.09.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  149 in total

Review 1.  Immune control by amino acid catabolism during tumorigenesis and therapy.

Authors:  Henrique Lemos; Lei Huang; George C Prendergast; Andrew L Mellor
Journal:  Nat Rev Cancer       Date:  2019-03       Impact factor: 60.716

Review 2.  Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.

Authors:  Xiaoyun Li; Mathias Wenes; Pedro Romero; Stanley Ching-Cheng Huang; Sarah-Maria Fendt; Ping-Chih Ho
Journal:  Nat Rev Clin Oncol       Date:  2019-07       Impact factor: 66.675

3.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

4.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

Review 5.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

6.  Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.

Authors:  Jun Li; Mercedes A Duran; Eileen E Parkes; Benjamin Izar; Ninjit Dhanota; Walid K Chatila; Sarah E Bettigole; John Kwon; Roshan K Sriram; Matthew P Humphries; Manuel Salto-Tellez; Jacqueline A James; Matthew G Hanna; Johannes C Melms; Sreeram Vallabhaneni; Kevin Litchfield; Ieva Usaite; Dhruva Biswas; Rohan Bareja; Hao Wei Li; Maria Laura Martin; Princesca Dorsaint; Julie-Ann Cavallo; Peng Li; Chantal Pauli; Lee Gottesdiener; Benjamin J DiPardo; Travis J Hollmann; Taha Merghoub; Hannah Y Wen; Jorge S Reis-Filho; Nadeem Riaz; Shin-San Michael Su; Anusha Kalbasi; Neil Vasan; Simon N Powell; Jedd D Wolchok; Olivier Elemento; Charles Swanton; Alexander N Shoushtari; Samuel F Bakhoum
Journal:  Cancer Discov       Date:  2020-12-28       Impact factor: 39.397

7.  Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.

Authors:  Yugang Guo; Yu-Qing Xie; Min Gao; Yang Zhao; Fabien Franco; Mathias Wenes; Imran Siddiqui; Alessio Bevilacqua; Haiping Wang; Hanshuo Yang; Bing Feng; Xin Xie; Catherine M Sabatel; Benjamin Tschumi; Amphun Chaiboonchoe; Yuxi Wang; Weimin Li; Weihua Xiao; Werner Held; Pedro Romero; Ping-Chih Ho; Li Tang
Journal:  Nat Immunol       Date:  2021-05-24       Impact factor: 25.606

8.  CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.

Authors:  Roberta Zappasodi; Inna Serganova; Ivan J Cohen; Masatomo Maeda; Masahiro Shindo; Yasin Senbabaoglu; McLane J Watson; Avigdor Leftin; Rachana Maniyar; Svena Verma; Matthew Lubin; Myat Ko; Mayuresh M Mane; Hong Zhong; Cailian Liu; Arnab Ghosh; Mohsen Abu-Akeel; Ellen Ackerstaff; Jason A Koutcher; Ping-Chih Ho; Greg M Delgoffe; Ronald Blasberg; Jedd D Wolchok; Taha Merghoub
Journal:  Nature       Date:  2021-02-15       Impact factor: 49.962

9.  An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.

Authors:  Olga Novikov; Zhongyan Wang; Elizabeth A Stanford; Ashley J Parks; Alejandra Ramirez-Cardenas; Esther Landesman; Israa Laklouk; Carmen Sarita-Reyes; Daniel Gusenleitner; Amy Li; Stefano Monti; Sara Manteiga; Kyongbum Lee; David H Sherr
Journal:  Mol Pharmacol       Date:  2016-08-29       Impact factor: 4.436

10.  Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy.

Authors:  Nobu Oshima; Ryo Ishida; Shun Kishimoto; Kristin Beebe; Jeffrey R Brender; Kazutoshi Yamamoto; Daniel Urban; Ganesha Rai; Michelle S Johnson; Gloria Benavides; Giuseppe L Squadrito; Dan Crooks; Joseph Jackson; Abhinav Joshi; Bryan T Mott; Jonathan H Shrimp; Michael A Moses; Min-Jung Lee; Akira Yuno; Tobie D Lee; Xin Hu; Tamara Anderson; Donna Kusewitt; Helen H Hathaway; Ajit Jadhav; Didier Picard; Jane B Trepel; James B Mitchell; Gordon M Stott; William Moore; Anton Simeonov; Larry A Sklar; Jeffrey P Norenberg; W Marston Linehan; David J Maloney; Chi V Dang; Alex G Waterson; Matthew Hall; Victor M Darley-Usmar; Murali C Krishna; Leonard M Neckers
Journal:  Cell Rep       Date:  2020-02-11       Impact factor: 9.423

View more
  6 in total

Review 1.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

2.  Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer.

Authors:  Jia Bo Zheng; Chau Wei Wong; Jia Liu; Xiao-Jing Luo; Wei-Yi Zhou; Yan-Xing Chen; Hui-Yan Luo; Zhao-Lei Zeng; Chao Ren; Xiao-Ming Xie; De-Shen Wang
Journal:  Oncoimmunology       Date:  2022-05-25       Impact factor: 7.723

3.  Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors.

Authors:  Xiaowei Liu; Cheng Cheng; Yuanxia Cai; Yaoyao Gu; Yangkun Wu; Kai Chen; Zhixiang Wu
Journal:  Int J Oncol       Date:  2022-04-15       Impact factor: 5.884

4.  Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.

Authors:  Shijie Mai; Liping Liang; Genghui Mai; Xiguang Liu; Dingwei Diao; Ruijun Cai; Le Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

Review 5.  The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment.

Authors:  Xintian Chen; Menghan Cao; Pengfei Wang; Sufang Chu; Minle Li; Pingfu Hou; Junnian Zheng; Zhongwei Li; Jin Bai
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

6.  Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses.

Authors:  Jeongrae Kim; Yongwhan Choi; Suah Yang; Jaewan Lee; Jiwoong Choi; Yujeong Moon; Jinseong Kim; Nayeon Shim; Hanhee Cho; Man Kyu Shim; Sangmin Jeon; Dong-Kwon Lim; Hong Yeol Yoon; Kwangmeyung Kim
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.